Dr. Lal PathLabs becomes South Asia's First Diagnostic Chain to Launch Advanced Test for Amyloidosis

Dr. Lal PathLabs Limited ("DLPL" / "Dr. Lal PathLabs"), a leader in diagnostic healthcare, has introduced Amyloid Typing by Laser Capture Microdissection & Mass Spectrometry - a breakthrough test for accurately identifying different types of Amyloid proteins. With this launch, DLPL becomes the first diagnostic chain in South Asia to offer this highly specialized test.

Amyloidosis is a disease where the abnormal or misfolded amyloid protein accumulates in various vital organs leading to loss of function or even death in some cases. More than 40 types of Amyloid proteins are discovered till date, and precise knowledge about the type of Amyloid helps doctors in choosing the correct treatment or management plan for the patient. Kidney, Heart, Lungs, Skin are the most common involved, however any organ in the body can be affected.

Key Highlights:

- First-of-its-kind in South Asia - DLPL pioneers this advanced diagnostic solution.

- Nationwide Availability - Samples can be collected from anywhere in India and sent to National Reference Lab, Rohini, New Delhi for testing.

- Accurate Diagnosis - Helps doctors determine the specific type of Amyloid, enabling targeted treatment and better outcomes.

- Access for Hospitals - All hospitals can facilitate sample collection for patients and send to Dr Lal PathLabs for testing.

Commenting on the launch, Mr. Shankha Banerjee, CEO of Dr. Lal PathLabs, said, "Our mission is to bring world-class diagnostics to India. By introducing this advanced Amyloidosis test, we aim to provide doctors with critical insights for accurate diagnosis and personalized treatment. We are proud to be the first diagnostic chain in South Asia to offer this cutting-edge solution."

Adding further, Dr. Alok Sharma, R&D Head & Director Renal Pathology & Electron Microscopy, stated, "Accurate typing of Amyloid proteins is essential for guiding treatment decisions. This gold standard advanced test, powered by Laser Microdissection & Mass Spectrometry allows us to precisely identify amyloid subtypes, helping clinicians provide targeted care. With this launch, we are bringing global standards of Proteomics based diagnostics to patients across India."

Dr. Lal PathLabs has launched this test, under the guidance of National Amyloidosis Centre, London (UK).

This innovation reaffirms Dr. Lal PathLabs' commitment to delivering advanced, accessible, and reliable diagnostic services across India.

Shares of Dr. Lal Path Labs Ltd. was last trading in BSE at Rs. 2699.85 as compared to the previous close of Rs. 2666.95. The total number of shares traded during the day was 4375 in over 851 trades.

The stock hit an intraday high of Rs. 2715.45 and intraday low of 2644.70. The net turnover during the day was Rs. 11706461.00.

Source : Equity Bulls

Keywords

DrLalPathLabs INE600L01024 HealthcareServices AmyloidTyping LaserCapture Microdissection MassSpectrometry